X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder. We show 17 historical shares outstanding datapoints in our coverage of XFOR's shares outstanding history.
Understanding the changing numbers of XFOR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XFOR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XFOR by allowing them to research XFOR shares outstanding history
as well as any other stock in our coverage universe. |